
Sweden’s Medical Products Agency advises people taking Mounjaro who rely on the contraceptive pill to add a barrier method, such as a condom or diaphragm, or switch contraceptive methods. The first four weeks after starting treatment are particularly important, as are the first four weeks after each dose increase, Ulla Wändel-Liminga, a scientific lead at the agency, told Dagens Nyheter.
In its November 20 report, the newspaper said pregnancies among women taking both Mounjaro and the pill prompted the European Medicines Agency to review whether the drug could affect how well the pill works. The European agency found limited evidence on that question for women with overweight, obesity or type 2 diabetes.
The advice to use backup contraception or switch methods is specific to Mounjaro, which contains tirzepatide. It does not currently extend to other GLP-1 medicines such as Ozempic, according to the report.
Sources
- Dagens Nyheter · Source date: 2026-11-20
Independent editorial content. WUA is not affiliated with any political party. 2026-11-20